Opportunity knocks for BeiGene

The success of Brukinsa sees BeiGene at an inflection point, and the pharma plans to leap at the 'once-in-a-lifetime' opportunity the blockbuster provides.

BeiGene saw net product revenue grow 73 per cent year-on-year to $6.07 billion (US$3.780 billion) in 2024, mostly on the back of BTK inhibitor Brukinsa, which saw global sales increase 105 per cent over that time to hit $4.24 billion (US$2.644 billion) for 2024.

"We have a once-in-a-lifetime opportunity to build life-changing combinations and the preeminent franchise in the $19.3 billion (US$12 billion)-plus CLL (chronic lymphocytic leukaemia) market," BeiGene CEO, John Oyler, told the company's earnings call.